Skip to main content

National Institutes of Health (NIH)

Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)

Request Ticket // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed, provided that each application is scientifically distinct.

Purpose
This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and a Scientific Catalyst program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in nutrition and obesity.

Funding Type
External Deadline
10/20/2026
Solicitation Type

Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)

No Applicants // Limit: 1 // Tickets Available: 1 

Limiting Language
Only one application per institution (normally identified by having a unique UEI number or NIH IPF number) is allowed.

Purpose
In response to a longstanding congressional mandate (P.L. 98-619, Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriation Act, 1985), NIMHD invites applications from eligible institutions to establish a national coordinating center (CC) for the Research Centers in Minority Institutions (RCMIs) initiative. The RCMI CC will coordinate activities across funded RCMI U54 Centers, prospectively evaluate the overall RCMI program, and serve as a national resource to help these centers achieve their primary goals. The RCMI CC will be responsive to requests generated by RCMI site key personnel, NIMHD, NIH, the scientific community, and the general public. 
 

Funding Type
External Deadline
8/7/2026

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) - PAR-23-286, PAR-23-287

Apply to Internal Competition // Limit: 4* (see below) // Tickets Available: 4

Cancer Data Science // Limit: 1 // Tickets Available: 1

Cancer Control Science // Limit: 1 // Tickets Available: 1 

Molecular Precision/Cancer Prevention // Limit: 1 // Tickets Available: 1 

Other Cancer Research // Limit: 1 // Tickets Available: 1

Limiting Language
Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286, PAR-23-287, and/or PAR-23-288 (archived)).

Scientific Areas

  • (A) Cancer Data Science: For the purposes of this K99/R00 award, cancer data science is defined as an interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are both developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This includes cancer-focused data integration and visualization, systems biology, artificial intelligence, machine learning, informatics, genomics, precision oncology, and developing analytics for epidemiological or biostatistical studies.
  • (B) Cancer Control Science: For the purposes of this K99/R00 award, cancer control science is defined as basic and applied research in the behavioral, social, and population sciences to create or enhance interventions that, independently or in combination with biomedical approaches reduce cancer risk, incidence, morbidity, and mortality, and improve quality of life. This includes research in epidemiology, behavioral sciences, health services, surveillance, cancer survivorship, and healthcare policy.
  • (C) Molecular/Precision Cancer Prevention: For the purpose of this K99/R00 award, early translational research in cancer prevention is defined as basic research to understand mechanisms of cancer formation, development and progression of cancer precursors, and to translate basic biological knowledge into novel human interventions and human-centered adaption of current interventions with the potential to reduce cancer risk, incidence, and mortality, and improve quality of life. This includes but is not limited to research in molecular and systems biology, diagnostics, vaccine and drug development, pharmacology, and biomedical engineering.
  • (D) Other Cancer Research: For the purposes of this K99/R00 award, "Other Cancer Research" includes all scientific fields supported by the NCI that are not included in (A), (B) or (C). Applicants proposing research in (D) "Other Cancer Research" may apply only if it is reasonable to expect their candidates to transition to independence with an abbreviated period of mentored research training beyond their original doctoral degrees."
Funding Type
External Deadline
10/14/2026
Internal Deadline
Internal Time
5:00PM
Solicitation Type

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.

Purpose
This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts

The RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design and analysis, 3) providing research coordination with a central laboratory, 4) harmonizing data collection methods and use of common data elements, 5) developing the database; 6) conducting data management and data analyses for Consortium studies; and 7) fostering research collaborations. This NOFO uses a cooperative agreement mechanism (U24) and runs in parallel with a companion NOFO (RFA-DK-27-121).

Full sponsor guidelines are linked here. 
 

Funding Type
External Deadline
10/9/2026
Internal Deadline
Internal Time
5:00PM
Solicitation Type

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.


Purpose
This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs.  Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. 

Full sponsor guidelines are linked here. 

Funding Type
External Deadline
10/9/2026
Internal Deadline
Internal Time
5:00PM
Solicitation Type

Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)

Request Ticket // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique entity identifier (UEI) number or NIH IPF number) is allowed.

Purpose
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for the Atopic Dermatitis Research Network (ADRN) program. The ADRN program will support Centers that integrate clinical and translational research to improve our understanding and management of atopic dermatitis with emphasis on chronic skin inflammation and the defense mechanisms of the skin.

Full sponsor guidelines are linked here. 

Funding Type
External Deadline
9/24/2026
Solicitation Type

Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed)

Institutionally Coordinated, please contact limited submissions if you are intersted in applying for the September 2026 deadline. 

Upcoming Webinar
July 8, 2026, at 1:00 pm (EST).

Please register using the link below to secure your spot.
https://scgcorp.zoom.us/webinar/register/WN_yoQC9j2mSAWyu7HcCxD8Dw#/registration 

Limiting Language
Applicant organizations may submit only one application, provided that the type of instrument does not currently exist in the applicant organization (identified by UEI).

Purpose
This Notice of Funding Opportunity (NOFO) aims to build new research capacity and develop a sustainable research program by supporting the purchase of a single commercially available biomedical research instrument currently unavailable in the institution. Instruments funded through this program must be shared among the users to create new research opportunities, enable reproducible data generation, encourage collaborative research and training, and strengthen long-term research capabilities. The minimum award is $50,000. While there is no limit on the total cost of the instrument, the maximum award is $400,000.

Research Category
External Deadline
9/25/2026
Solicitation Type

Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)

Institutionally Coordinated, please contact limited submissions if you are intersted in applying for the July 2026 deadline. 

Per NIH, proposals submitted to the 6/1/2026 SIG deadline should not be resubmitted to the 7/27/2026 deadline. 

Limiting Language
The University of Arizona may submit more than one proposal provided that each application is scientifically distinct. This is an Institutionally Coordinated Submission. 

Purpose
This Notice of Funding Opportunity (NOFO) announces the restructured Shared Instrumentation Grant (SIG) Program that consolidates three existing shared-use instrumentation programs, i.e., the Shared Instrumentation Grant program, the High-End Instrumentation Grant program, and the Basic Instrumentation Grant program. The NOFO invites applications from groups of NIH-supported investigators to purchase or upgrade a single state-of-the-art commercially available instrument or an integrated instrumentation system. The instruments purchased through the SIG Program are required to be optimally shared among the users to ensure efficient and cost-effective research operations, enable rigorous and reproducible measurements, and encourage collaborative research and benefit broad research communities at large. The minimum award is $300,000. There is no cap on the total cost of the instrument; however, the maximum award is $5,000,000.

Research Category
External Deadline
7/27/2026

NIH Director's Early Independence Award (DP5 Clinical Trial Optional)

Request Ticket // Limit: 2 // Tickets Available: 2

Limiting Language 
Only two applications per institution (identified by Unique Entity Identifier (UEI) number or NIH IPF number) are allowed.


Program Description
Full sponsor guidelines are linked here.

The NIH Director's Early Independence Award helps talented new researchers begin their own independent research program soon after finishing their doctoral degree or clinical training, without first doing postdoctoral training.The award accepts applications on any topic fitting the NIH mission. It is part of the NIH Common Fund's High-Risk, High-Reward Research program.

Eligible Individuals (Program Director/Principal Investigator)
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. 

Requirements

  • One PD/PI only: Applications can have only one PD/PI. Multiple PD/PIs are not allowed. Only the PD/PI may be listed as Senior/Key Personnel and submit a biosketch.
  • Citizenship: U.S. citizenship is not required. If the PD/PI is not a U.S. citizen, the institution must ensure the visa permit allows them to do the proposed research in the U.S. for the full project period.
  • Degree or clinical training dates: The PD/PI must complete their terminal doctoral degree or post-graduate clinical training between May 1, 2025, and September 30, 2027.
    • The date shown on the official transcript is considered the date the degree was completed.
    • Clinical training includes residency and fellowship.
    • At the time of award, either:
      • The PD/PI must have an eligible doctoral degree from an accredited U.S. or foreign institution, oR
      • An authorized official must confirm all degree requirements are complete and the degree will be awarded before September 30, 2027.
  • Post-doctoral experience: The PD/PI must not have more than 12 months of postdoctoral training after an earlier, non-terminal doctoral degree. This applies only to individuals with multiple doctoral degrees.
  • Effort required:
    • Years 1-2: At least 9.6 person-months per year (80% effort) on the award project
    • Years 3-5:  At least 9.6 person-months per year (80% effort) on independent research overall, including the award project and any other independent research led by the PD/PI.
  • Non-independence required: At the time of application, the PD/PI must still be non-independent. All the following must apply:
    • Research direction requires mentor approval
    • Research is mainly supported through another investigator's funding (mentored fellowships, such as an NIH F31/F32 or NSF Graduate Research Fellowship, do not make an applicant ineligible)
    • No institutionally assigned research space
    • Cannot apply for an NIH R01 without a special institutional waiver or exception

The PD/PI may become independent before the award starts and still remain eligible.

  • Independent position required: The PD/PI must have a guaranteed, pending independent research position and be able to begin independent research by the project start date.
    • The position does not have to be permanent or tenure-track.
    • The position may depend on receiving this award.
    • The institution must provide substantial support, as described in the application.
    • Moving to a new institution may be advantageous but is not required.
  • Career awards: ThePD/PI may apply for both a K award and DP5 simultaneously, but the projects must not overlap scientifically. A PD/PI cannot hold both simultaneously; if awarded the DP5, the K award must be relinquished.
  • Site visit: NIH will conduct a site visit near the end of the first year to assess progress and confirm institutional support and independence. If support is insufficient, NIH may take corrective action, including reducing or terminating funding.
Funding Type
External Deadline
9/10/2026
Internal Deadline
Solicitation Type